

To the attention of Bei Erez company,
Israel

Lyon, France
September 13th, 2021

On behalf of Boehringer–Ingelheim company, I would like to inform you about the current situation and developments for the 2022 tender in Israel for VPH range of products.

The already known price movement in many areas of our production industry and transportation does not stop. Considering this situation, for the coming 2022, we are also forced to raise the prices of our VPH supplied products.

Attached you may find the new price offer, valid from January 1st, 2022 valid for the period of VPH tender in the country.

We have to raise significantly our prices for Rabisin especially by more than 50% due to production costs constrains in our company and we have no choice to dramatically increase our price.

Regarding Raboral and FMD vaccines, our company did not increase prices from over last 6 years for tenders and this is mainly production costs increase as well as inflation effect.

We will raise our Raboral price by 10% and FMD range of products by 4% for next year tender.

I hope you will understand that our products are valuable ones that cannot be sold under their production costs.

Should you need any further information, I remain at your disposal.

With best regards

A.BASSI
Regional Commercial Business Manager EUCAN. VPH

A. Bassi

Boehringer
Ingelheim
Boehringer Ingelheim Animal Health France
29, avenue Tony Garnier
69007 LYON
+33 4 72 72 30 00

**Boehringer Ingelheim
Animal Health France**
Site de Boreal
29 avenue Tony Garnier
69007 Lyon – France
Tel. : +33 (0)4 72 72 30 00
Fax : +33 (0)4 72 72 34 91
www.boehringer-ingelheim.fr

Boehringer Ingelheim Animal Health France
siège social au
29 avenue Tony Garnier
69007 Lyon – France
société en commandite simple
au capital de 23 743 685,75 euros
590 800 215 R.C.S. LYON

